| Singapore
: The Institute of Bioengineering and Nanotechnology
(IBN) has developed a novel method to simultaneously
control the size and morphology of nanoparticles, which
can be used in pharmaceutical synthesis and novel biomedical
applications.
This groundbreaking research
was recently featured in the leading Chemistry journal,
Angewandte Chemie1, and a United States patent has
been filed on the invention.
Research Scientist Dr. Yu Han
and IBN Executive Director Prof. Jackie Y. Ying have
developed a fluorocarbon-mediated-synthesis technique
that produces nanometer-sized particles of between
50 and 300 nm with tunable pore sizes in the range
of 5-30 nm (The width of a human hair is approximately
80,000 nm).
“The nanoporous nanoparticles
are named after our Institute, termed ‘IBN-1’ to ‘IBN-5’.
They represent a new class of materials that are tailored
simultaneously with nanometer-scale particle size
and nanometer-sized pores. This is a beautiful example
of ‘bottom-up’ nanotechnology made possible by supramolecular
chemistry,” said Prof. Ying.
Previous attempts at synthesizing
such nanoparticles created particles that were limited
in the type of structure, degree of structural ordering
and range of pore sizes. Most current technologies
can only produce 2-dimensional hexagonal structure
with small pore diameter (< 5 nm). In many cases,
special vapor-phase synthesis equipment is required.
IBN’s simple wet-chemical technique
uses two different types of surfactant (a soluble
chemical compound that reduces the surface tension
between liquids). One surfactant acts as the template
for mesoporous structure, while the other is used
to limit the growth of the particles to nanometer
dimensions.
This method can be used to
create a variety of nanoparticles with enormous surface
areas, and very well-defined pore size and structure.
One important application of
these nanoporous nanoparticles lies in the production
of pure chiral drugs, which make up over one-third
of all pharmaceutical drugs currently sold worldwide.
Chiral drugs are comprised of “left-handed” and “right-handed”
molecules, both of which are mirror images of each
other. Only one of these molecules provides the therapeutic
effect. In the production process, catalysts are used
to selectively synthesize the preferred chiral molecule
that provides for therapeutic treatment without undesired
side-effects. However, these catalysts normally exist
in a homogeneous liquid phase, which makes them difficult
to be separated and reused.
Prof. Ying’s group at IBN has
developed novel approaches to immobilize these catalysts
on nanoporous materials synthesized by its wet-chemical
technique. This renders the catalysts in a solid form,
enabling them to be easily recovered and reused through
simple filtering or centrifuging processes. This allows
for the more efficient synthesis of a wide variety
of pharmaceuticals.
This improvement in the drug
manufacturing process can potentially lead to greater
cost savings, as the production of the chiral ingredient
currently accounts for 10-40% of the total cost. IBN’s
invention could potentially have a significant impact
on the chiral pharmaceuticals industry, a fast-growing
sector which generated US$143 billion sales in 2003.
Other applications of IBN’s
nanoporous nanoparticles involve therapeutic treatments
like targeted drug delivery and gene therapy. Nanoparticles
of varying size and structure may be created to act
as carriers for drugs, genes and proteins. In addition,
these porous nanoparticles can be used to host quantum
dots and magnetic nanoparticles for bioimaging and
quantum device applications.
1
Y. Han and J. Y. Ying, “Generalized Fluorocarbon-Surfactant-Mediated
Synthesis of Nanoparticles with Various Mesoporous
Structures,” Angewandte Chemie International Edition,
44 (2004) 288-292
The
Institute of Bioengineering and Nanotechnology (IBN)
was established to spearhead the advancement of biomedical
sciences in Singapore. Positioned at the interface
of two frontiers of engineering, IBN is focused on
creating knowledge and cultivating talent to develop
technology platforms that will spur the growth of
new industries. A member of the A*STAR's biomedical
sciences institutes, IBN is a leading national program
with an international vision and a dynamic interdisciplinary
research environment.
http://www.ibn.a-star.edu.sg/corporate_main.php
|